UFPG
MRKR icon

United Financial Planning Group’s Marker Therapeutics MRKR Stock Holding History

United Financial Planning Group’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250
Closed -$373 – 555
2025
Q4 		$373 Buy
+250
New +$283 ﹤0.01% 419

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

United Financial Planning Group's MRKR Position: Q1 2026 in Review

United Financial Planning Group sold out of Marker Therapeutics (MRKR) in Q1 2026, closing a stake of 250 shares — an estimated $373 sold.

United Financial Planning Group first reported a position in MRKR in Q4 2025 and held it in 1 quarter. The position peaked at $373 in Q4 2025. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

  • United Financial Planning Group reported no remaining Marker Therapeutics position as of Q1 2026 after selling out during the quarter.
  • United Financial Planning Group sold 250 Marker Therapeutics shares in Q1 2026, an estimated $373.
  • United Financial Planning Group first reported a position in Marker Therapeutics in Q4 2025 and held it in 1 quarter.
  • United Financial Planning Group's Marker Therapeutics position peaked at $373 in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on United Financial Planning Group's 13F filing for Q1 2026, filed 8 May 2026.